Filing Flows › Guardant Health (GH) › Q3 2026 › vs Q3 2025
Guardant Health (GH) Q3 2026 vs Q3 2025 (year over year)
Guardant Health's revenue rose $95.8M (+36%) from $265M in Q3 2025 to $361M in Q3 2026. The biggest changes: Oncology +$46.9M (+25%); Screening +$43.5M (+180%); Biopharma and data +$4.2M (+8%).
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Oncology | $231M | $184M | $46.9M | +25% |
| Screening | $67.6M | $24.1M | $43.5M | +180% |
| Biopharma and data | $59.0M | $54.7M | $4.2M | +8% |
| Licensing and other | $3.1M | $2.0M | $1.2M | +60% |
| Revenue | $361M | $265M | $95.8M | +36% |
| Other income, net | $8.7M | $6.4M | $2.3M | +37% |
| Net loss | $124M | $92.7M | $31.6M | +34% |
| Costs & expenses | $494M | $364M | $130M | +36% |
| Operating costs | $494M | $364M | $130M | +36% |
| Income tax | $343K | $136K | $207K | +152% |
| Cost of revenue | $125M | $93.6M | $31.2M | +33% |
| Research & development | $101M | $90.0M | $10.9M | +12% |
| Sales & marketing | $177M | $127M | $49.8M | +39% |
| General & admin | $90.9M | $53.3M | $37.6M | +71% |
| Operating cash sources | $124M | $92.7M | $31.6M | +34% |
| Depreciation & amortization | $10.2M | $9.4M | $770K | +8% |
| Share-based compensation | $62.4M | $42.8M | $19.6M | +46% |
| Working capital & other | $28.0M | $5.1M | $22.9M | +450% |
| Cash used in operations | $23.7M | $35.4M | −$11.7M | -33% |
| Net loss absorbed | $124M | $92.7M | $31.6M | +34% |
Questions
How much did Guardant Health's revenue grow year over year in Q3 2026?
Guardant Health's revenue rose $95.8M (+36%) from $265M in Q3 2025 to $361M in Q3 2026.
What drove Guardant Health's revenue change in Q3 2026?
Oncology +$46.9M (+25%); Screening +$43.5M (+180%); Biopharma and data +$4.2M (+8%).